Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -540%. A quarter ago, it was expected that this drug developer would post a loss of $0.21 per share when it actually produced a loss of $0.62, delivering a surprise of -195.24%.Over the last four quarters, the company ...